SMAD3, Cell Proliferation and Lymph Nodes Metastasis in Breast Cancer Hormone-dependent

Overview

Journal Tunis Med

Specialty General Medicine

Date 2023 Sep 8

PMID 37682272

Authors

Mohamed Oueslati

Nadia Sassi

Ilhem Bettaieb

Amor Gamoudi

Khaled Rahal

Ridha Oueslati

Affiliations

Soon will be listed here.

Abstract

Introduction: Tumor Growth Factor-β (TGF-β) is a multifunctional cytokine that plays a crucial role in various biological processes. TGF-β is also involved in various pathologies including breast cancer (BC). BC is strongly dependent on hormone receptors such as Estrogen receptors (ERa, ERb) and Progesterone Receptor (PR).

Aim: To audit the potential cross-talk between TGF-β and the molecular distribution of hormone receptors (ERs and PR).

Methods: The current study analyzes the expression patterns of SMAD3, ERα, ERβ and PR in 40 breast tumor tissues using qRT-PCR. Furthermore, the Ki-67 and HER2/neu status have been detected by Immunohistochemistry.

Results: Our results show a decrease in the SMAD3 expression in 27 of the 40 cases while its expression is increased in the remaining 13 cases (p=0.003). The over-expression of SMAD3 is associated with high tumor grades. Moreover, there is a significant positive correlation between SMAD3+ with a high proliferative index and metastases (p=0.001 and p=0.01respectevely). The SMAD3 expression relative to (ERα, ERβ) subgroups shows a significant association of SMAD3+ with the (ERα+, ERβ+) subgroups (p=0.009). The same is true for PR, our results show a significant association of SMAD3+ with PR+ (p=0.02). Moreover, analysis of the expression of molecular subgroups (SMAD3+, ERα+, ERβ+) and (SMAD3+, PR+) compared to clinical and pathological information shows a significant association with high grade tumors, a high proliferation index (p=0.02, p= 0.01 respectively) and lymph node infiltration.

Conclusion: It is concluded that SMAD3 can promote cell proliferation and metastases in (ERα+, ERβ+) and PR+ breast cancer.

References

Zhong Q, Wang T, Lu P, Zhang R, Zou J, Yuan S . miR-193b promotes cell proliferation by targeting Smad3 in human glioma. J Neurosci Res. 2014; 92(5):619-26. DOI: 10.1002/jnr.23339. View

Oueslati M, Bittaieb I, Sassi N, Ben Jemaa A, Gamoudi A, Rahal K . ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity. Oncol Lett. 2017; 14(2):1675-1682. PMC: 5542036. DOI: 10.3892/ol.2017.6314. View

Joshi P, Jackson H, Beristain A, Di Grappa M, Mote P, Clarke C . Progesterone induces adult mammary stem cell expansion. Nature. 2010; 465(7299):803-7. DOI: 10.1038/nature09091. View

Petersen M, Pardali E, Van Der Horst G, Cheung H, van den Hoogen C, van der Pluijm G . Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene. 2009; 29(9):1351-61. DOI: 10.1038/onc.2009.426. View

Moustakas A, Heldin C . Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007; 98(10):1512-20. PMC: 11158989. DOI: 10.1111/j.1349-7006.2007.00550.x. View

Chaudhury A, Howe P . The tale of transforming growth factor-beta (TGFbeta) signaling: a soigné enigma. IUBMB Life. 2009; 61(10):929-39. PMC: 2810629. DOI: 10.1002/iub.239. View

Reiss M, Barcellos-Hoff M . Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat. 1997; 45(1):81-95. DOI: 10.1023/a:1005865812918. View

Speirs V, Parkes A, Kerin M, Walton D, Carleton P, Fox J . Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?. Cancer Res. 1999; 59(3):525-8. View

Haque S, Morris J . Transforming growth factor-β: A therapeutic target for cancer. Hum Vaccin Immunother. 2017; 13(8):1741-1750. PMC: 5557219. DOI: 10.1080/21645515.2017.1327107. View

10.

Lin Z, Reierstad S, Huang C, Bulun S . Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res. 2007; 67(10):5017-24. DOI: 10.1158/0008-5472.CAN-06-3696. View

11.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

12.

Chen P, Li B, Ou-Yang L . Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022; 13:839005. PMC: 9433670. DOI: 10.3389/fendo.2022.839005. View

13.

Skliris G, Leygue E, Watson P, Murphy L . Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol. 2008; 109(1-2):1-10. DOI: 10.1016/j.jsbmb.2007.12.010. View

14.

Coffey Jr R, Bascom C, Sipes N, Weissman B, Moses H . Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol. 1988; 8(8):3088-93. PMC: 363535. DOI: 10.1128/mcb.8.8.3088-3093.1988. View

15.

Piasecka D, Skladanowski A, Kordek R, Romanska H, Sadej R . [Aspects of progesterone receptor (PR) activity regulation - impact on breast cancer progression]. Postepy Biochem. 2015; 61(2):198-206. View

16.

Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L . Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer. 2006; 95(5):616-26. PMC: 2360679. DOI: 10.1038/sj.bjc.6603295. View

17.

Xu J, Lamouille S, Derynck R . TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19(2):156-72. PMC: 4720263. DOI: 10.1038/cr.2009.5. View

18.

Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E . TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996; 10(19):2462-77. DOI: 10.1101/gad.10.19.2462. View

19.

Trabert B, Sherman M, Kannan N, Stanczyk F . Progesterone and Breast Cancer. Endocr Rev. 2019; 41(2). PMC: 7156851. DOI: 10.1210/endrev/bnz001. View

20.

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View